Enumeral gets Phase II SBIR contract from NCI to advance human tissue immuno-oncology profiling

The company will be developing an advanced, automated prototype system for human tissue immuno-oncology profiling, which it will deploy at two leading medical institutions over the course of the contract. The NCI will be funding the entirety of the program, which will complement Enumeral’s other internal research and development efforts.

Small volume clinical specimens such as core biopsy or fine needle aspirates often contain limited numbers of cells and can be challenging to analyze with conventional technologies.

This Phase II program utilizes Enumeral’s platform to obtain multiplexed information from human tissue samples of limited cellularity, potentially addressing these challenges. Enumeral generated proof of concept in this area under a Phase I contract in 2012 and 2013.

"We expect our continued relationship with the NCI will further enhance our capabilities in high resolution analysis of cellular function in the tumor microenvironment. We look forward to expanding our relationships with leading medical institutions, which will apply these advancements in translational and clinical research settings," said Arthur H. Tinkelenberg, Ph.D., President, Chief Executive Officer and Co-Founder of Enumeral.

"We believe that measurements of lymphocyte function directly in human tissues will deepen our understanding of cancer progression and will accelerate development of novel and best-in-class immunomodulators."